Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Maintenance in NSCLC: Q & A

Future Horizons in Lung Cancer

Sorry, this item is currently unavailable.

Published: 5 Oct 2016

Views: 1734

Rating:

Save

Dr Besse and Dr Bhosle

Dr Besse and Dr Bhosle discuss and answer questions arising from debate on the merits or lack thereof of maintenance as a treatment strategy in NSCLC.

Related Videos

Biomarkers, predictive and prognostic factors of resistance to immunotherapy

Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)...

Biomarkers, predictive and prognostic factors of resistance to immunotherapy ( Dr Ignacio Gil-Bazo - Fundación Instituto Valenciano de Oncología (FIVO)/Clínica Universidad de Navarra, Spain )

Research highlights in lung cancer

Dr Meri Muminovic - Memorial Cancer Institute, Miami, USA

Research highlights in lung cancer ( Dr Meri Muminovic - Memorial Cancer Institute, Miami, USA )

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy...

Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel

Blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell lung cancer ( Prof Jair Bar - Sheba Medical Center, Tel-Aviv, Israel )

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during...

Prof Gerard Zalcman - Université de Paris, Paris, France

Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients ( Prof Gerard Zalcman - Université de Paris, Paris, France )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC

Dr Stephen Chun - MD Anderson, Houston, USA

The 5-year long-term outcomes of radiation technique for locally advanced NSCLC ( Dr Stephen Chun - MD Anderson, Houston, USA )

OncoAlert Round Up for August 4th - 10th, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 4th - 10th, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity...

Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain

Tusamitamab ravtansine combined with SoC shows encouraging anti-tumour activity for patients with nonsquamous NSCLC ( Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain )

More from ecancer